Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.39 |
| ▸ | IDH2 | P48735 | 1/20 | 0.37 |
| ▸ | TLK2 | Q86UE8 | 4/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 3/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394471 | 0.93 | NTRK1 (0.40) | MAPK14TLK2NTRK1TP53SMN1; SMN2 | |
| SCHEMBL396420 | 0.89 | MAPK14 (0.45) | MAPK14IDH2TLK2NTRK1GSK3B | |
| SCHEMBL396166 | 0.89 | TLK2 (0.47) | MAPK14TLK2NTRK1JAK3GSK3B | |
| SCHEMBL395038 | 0.87 | MAPK14 (0.38) | MAPK14TLK2NTRK1JAK3GSK3B | |
| SCHEMBL396344 | 0.86 | FLT3 (0.47) | MAPK14IDH2TLK2NTRK1 | |
| SCHEMBL397245 | 0.85 | MAPK14 (0.37) | MAPK14TLK2NTRK1JAK3GSK3B | |
| SCHEMBL395533 | 0.85 | FLT3 (0.48) | TLK2NTRK1JAK3GSK3B | |
| SCHEMBL396893 | 0.84 | FLT3 (0.47) | TLK2NTRK1JAK3GSK3B | |
| SCHEMBL398246 | 0.84 | NTRK1 (0.53) | MAPK14TLK2NTRK1 | |
| SCHEMBL393773 | 0.84 | TLK2 (0.48) | TLK2NTRK1JAK3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | claimed |
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |